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Weight Loss Decreases Follicle Stimulating Hormone
in Overweight Postmenopausal Women
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Elizabeth Barrett-Connor6
Objectives: To examine the impact of a weight loss intervention upon follicle stimulating hormone (FSH)
levels in postmenopause.
Methods: Participants were postmenopausal, overweight, glucose-intolerant women not using exoge-
nous estrogen (n5382) in the Diabetes Prevention Program. Women were randomized to intensive life-
style change (ILS) with the goals of weight reduction of at least 7% of initial weight and 150 min per
week of moderate-intensity exercise, metformin 850 mg twice a day, or placebo administered twice a
day.
Results: Randomization to ILS led to small increases in FSH between baseline and 1-year follow-up vs.
placebo (2.3 IU/l vs. 20.81 IU/l, P < 0.01). Increases in FSH were correlated with decreases in weight
(r520.165, P < 0.01) and estradiol (E2) (r520.464, P < 0.0001) after adjustment for age, race/ethnicity,
and randomization arm. Changes in FSH were still significantly associated with changes in weight even
after adjustment for E2 levels. Metformin users had reductions in weight but non-significant changes in
FSH and E2 levels vs. placebo.
Conclusions: Weight loss leads to small increases in FSH among overweight, postmenopausal women,
potentially through pathways mediated by endogenous estrogen as well as other pathways.
Obesity (2015) 23, 228–233. doi:10.1002/oby.20917
Introduction
Menopause, the permanent cessation of menstruation and fertility,
has been classically characterized by elevated follicle stimulating
hormone (FSH) and very low estradiol (E2) levels. Obesity may
modify this relationship: FSH levels tend to rise more gradually and
attain lower levels in overweight and obese women compared to
lean women (1). In one report, about 20% of obese women had FSH
levels <30 IU/l at 1 year after menopause, compared to about 2%
of women of normal weight (2). The lower levels of FSH in over-
weight postmenopausal women compared to lean women have been
attributed to increased production of endogenous estrogens by mes-
enchymal adipose tissue (3), which could potentially act centrally to
decrease FSH. This is in agreement with randomized trials of
estrogen therapy, which demonstrate that randomization to either
low or higher-dose estrogen therapy results in increased serum E2
(4) and a decline in FSH levels in both lean and obese women (5,6).
Because of FSH fluctuations in the months surrounding the final
menstrual period as well as lower levels in obese women, FSH is
not currently recommended as a diagnostic test for menopause.
However, the link between adiposity and FSH is based on observa-
tional studies which generally document increases in both body
weight and serum FSH with chronological and reproductive aging.
Randomized studies of FSH responses to weight loss interventions
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in postmenopausal women are lacking. Because it is unknown
whether weight loss results in significant increases in FSH levels, it
is not clear whether associations between adiposity and FSH reflect
other factors associated with aging. In addition, studies have gener-
ally compared lean women to those who are overweight and obese.
It is possible that hypothalamic-pituitary-gonadal axis sensitivity is
relatively reduced in obese women (7), and therefore it is unknown
if FSH levels would be sensitive to weight loss among mid-life
women who are overweight and obese, currently 66% of mid-life
women (8). It is unknown whether any FSH changes would be pri-
marily explained by an increase in endogenous estrogens such E2,
or whether weight loss is still associated with FSH even after con-
sideration of E2 levels. It is possible that changes in adipose tissue
volume modify FSH via other markers apart from estrogens; obser-
vational studies suggest that increases in waist circumference in the
perimenopause predict changes in FSH, even prior to significant
declines in E2 (9). Moreover, among premenopausal women, over-
weight women have lower FSH levels than lean women, despite
similar or even lower E2 levels (10).
We (11) and others (12-14) have previously reported upon sex hor-
mones among glucose intolerant women, and specifically that higher
levels of E2 and lower levels of sex hormone binding globulin are
associated with poorer glucose tolerance. However, FSH, a compo-
nent of the hypothalamic-pituitary-gonadal axis which regulates sex
steroid production, has not been as extensively characterized. It is
not known whether FSH levels continue to be low further from the
final menstrual period in overweight and obese women with glucose
intolerance, whether FSH levels would increase to an extent that
would be clinically significant in response to weight loss, and to
what extent FSH reflects sex steroid levels vs. other factors. The
Diabetes Prevention Program (DPP) randomized overweight
glucose-intolerant participants to a program of intensive lifestyle
modification (ILS), metformin, or placebo (15). Participants random-
ized to interventions had maximal weight loss at 1 year after ran-
domization (15), and we have previously reported that this pattern
was also observed in the subpopulation of postmenopausal women
(11). To determine the impact of intentional weight loss on FSH lev-
els, we conducted a secondary analysis where we examined the
association between randomization assignment and changes in FSH
between baseline and 1 year, as well as the correlation between the
magnitude of changes in FSH, weight, waist circumference, and
serum E2 among women who did not use estrogen therapy. We
hypothesized that randomization to ILS would lead to increases in
FSH, which would be correlated with decreases in weight and waist
circumference. We also hypothesized that changes in FSH would be
correlated with changes even after adjustment for E2 levels.
Methods
Characteristics of DPP participants have been reported (15). Briefly,
the DPP inclusion criteria included age  25 years, body mass index
(BMI) 24 kg/m2 (22 kg/m2 for Asian Americans), and a fasting
plasma glucose of 95-125 mg/dl and 2-h plasma glucose of 140-200
mg/dl following a 75-g glucose load. Written informed consent was
obtained from all participants before screening, consistent with the
guidelines of each participating center’s institutional review board.
Eligible DPP participants were randomly assigned to one of three
interventions: 850 mg metformin twice daily, placebo twice daily, or
ILS. The goals of ILS were to achieve and maintain a weight reduc-
tion of at least 7% of initial body weight through consumption of a
low-calorie, low-fat diet, plus moderate physical activity for at least
150 min per week (15). Dietary intake was assessed by interview
using a modified Block food-frequency questionnaire (16). Total
MET-hours per week of physical activity were assessed by the 1-
year recall Modifiable Activity Questionnaire (17). Weight and waist
circumference were measured semiannually. At the time of random-
ization, all women completed a questionnaire about their menses,
gynecological history including surgeries, and estrogen use (contra-
ceptive and postmenopausal therapy). Medication use was reassessed
every 6 months.
Participants in this ancillary study included women who were post-
menopausal at randomization, who had an available stored blood
sample, and who consented for participation in ancillary studies.
Women were classified as postmenopausal if they met any of the
following criteria: bilateral oophorectomy, lack of menses for at
least one year while retaining uterus and at least one ovary, cessa-
tion of menses prior to hysterectomy, or cessation of menses with
hysterectomy and age  55 years. For the purposes of this report,
we examined two postmenopausal women who did not use estrogen
or testosterone therapy at baseline or 1-year follow-up (n5 382).
Women who used any type of estrogen therapy at either baseline,
interim, or 1-year follow-up were excluded.
Venous blood was sampled between 7 a.m. and 11 a.m. after an
overnight fast. FSH was measured at Endoceutics using ELISA
(Bioline) with interassay coefficients of variation of 3.6 and 4.4 at
27.1 and 72.9 mIU/ml, respectively. E2 was analyzed using gas
chromatography/mass spectrometry at Endoceutics; these methods
have been previously described (11). The limits of detection were
3.0 pg/ml for total E2 with an interassay coefficient of variation for
E2 at 17.5% at 4.7 pg/ml. We have previously reported (11) that
bioavailable levels of E2 (accounting for serum levels of sex hor-
mone binding globulin) were calculated according to the method
described by Sodergard and colleagues (courtesy of Frank Stanczyk,
University of Southern California) assuming a fixed albumin con-
centration of 4.0 g/dl (18). Associations between randomization arm
and E2 levels were similar for analyses examining bioavailable frac-
tions compared to total hormone levels, so only results with total
hormone levels are presented.
Statistical analysis
Baseline characteristics were described using percentages for cate-
gorical variables and means (SD) for quantitative variables. For vari-
ables where the distribution was skewed, median values were pre-
sented as indicated in Table 1. To assess the association between
randomization assignment and changes in weight and waist circum-
ference, T tests were used to compare changes by randomization
arm. ANOVA was used to determine if there were significant differ-
ences in the mean values across groups. Change was calculated as
year 1 hormone level–baseline hormone level. Changes in FSH and
E2 between baseline and year 1 follow-up, as well as measures of
physical activity and dietary intake, were not normally distributed,
so we used Wilcoxon rank-sum tests to compare changes between
randomization arms in pairwise comparisons and log-transformed
measures for comparisons in mean values across groups.
To determine if the observed changes in FSH between baseline and
year 1 were associated with changes in weight, waist circumference,
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and E2 levels between baseline and year 1, we used partial Pearson
correlation coefficients to estimate the relationship between FSH
and each of these measures, after adjustment for randomization arm.
We also adjusted for age and race/ethnicity, as these variables have
been previously been reported to be associated with FSH (2,19). To
determine whether associations between changes in FSH and
changes in weight and waist circumference were present after adjust-
ment for changes in E2, we created an additional set of coefficients
that adjusted for changes in E2 levels. The SAS analysis system was
used for all analyses (SAS Institute, Cary, NC).
Results
Baseline characteristics of the postmenopausal cohort are shown in
Table 1. Reflecting DPP recruitment criteria, all women were over-
weight or obese at baseline. Approximately 15 years had elapsed
since the last menstrual period, and about one quarter of women had
experienced their final menstrual period at 7 years prior to random-
ization. There were no significant differences at baseline between
women randomized to ILS (n5 133), metformin (n5 122), or pla-
cebo (n5 129), the exception that women randomized to metformin
had slightly lower levels of FSH. Changes in anthropometrics, FSH,
and E2 by randomization arm are shown in Table 2. Randomization
to ILS led to significant reductions in percent calories from fat and
increases in physical activity compared to placebo. Randomization
to ILS or metformin led to significant reductions in weight, waist
circumference, and BMI compared to placebo. Significant increases
in FSH were observed among women randomized to ILS compared
to placebo, although these differences were relatively small com-
pared to the mean baseline FSH value. Significant increases in FSH
were not observed among women randomized to metformin com-
pared to placebo. Significant changes in E2 were not observed by
randomization arm.
Shows partial correlation coefficients between changes in FSH with
changes in weight, waist circumference, and E2 after adjustment for
age, race/ethnicity, and randomization arm. FSH changes were
inversely associated with changes in weight, waist circumference,
and E2, with the strongest associations observed between changes in
FSH and changes in E2. Correlations between changes in FSH and
changes in weight (r520.165, P5 0.003) remained significant
after further adjustment for changes in E2 (r520.130, P5 0.036),
suggesting that changes in FSH were partially but not entirely
explained by changes in E2. Correlations between changes in
FSH and changes in waist circumference (r520.142, P5 0.011)
were of borderline significance after further adjustment for changes
in E2 (r520.109, P5 0.069). To determine whether time closer to
the last menstrual period was associated with greater FSH changes,
we conducted analyses that stratified by time elapsed since the last
menstrual period in the most recent quartile (<7 years) vs. longer
(results not shown). Similar patterns were observed among
TABLE 1 Baseline characteristics of participants unless otherwise indicated; change indicates difference between baseline
and year 1
Overall Lifestyle Metformin Placebo
n5382 n5 133 n5122 n5 127
Age (years) 58.7 (9.0) 59.2 (9.1) 57.9 (8.8) 59.0 (9.2)
Race/ethnicity
Caucasian 53 18 15 19
African-American 28 9 10 9
Hispanic 16 6 5 5
Asian 3 2 1 0
Type of menopause
Bilateral oophorectomy 20 8 6 6
Natural menopause 67 24 21 22
Age  55 years and hysterectomy 16 4 4 5
Hysterectomy 37 13 12 12
Years since final menstrual period 15 (10) 15 (10) 15 (11) 14 (9)
Alcohol intake per day (grams) 1.26 (2.90) 1.73 (3.70) 0.89 (2.20) 1.11 (2.47)
Total caloric intake per day (kcal) 1876 (956) 1855 (895) 1876 (975) 1897 (1006)
Percent calories from fat 32.9 (7.4) 32.5 (7.4) 33.9 (6.8) 32.4 (7.8)
Leisure-time physical activity (MET-hours/week) 13.5 (19.0) 12.6 (21.4) 12.5 (13.7) 15.6 (20.6)
Baseline weight (kg) 91.0 (19.7) 89.0 (19.8) 92.9 (20.8) 89.9 (18.5)
Baseline waist circumference (cm) 104 (14) 103 (14) 105 (14) 104 (14)
Baseline BMI (kg/m2) 34.6 (6.8) 34.1 (6.7) 35.2 (7.1) 34.5 (6.6)
Baseline FSH (IU/l) 55.3 (26.6) 54.8 (28.6) 51.5 (24.2)* 59.3 (26.1)
Baseline SHBG (nmol/L), median (IQR) 33.2 (18.3) 34.5 (17.8) 31.6 (17.1) 34.0 (21.8)
Baseline total E2 (pg/ml), median (IQR) 8.5 (8.0) 8.3 (7.6) 9.2 (7.0) 8.4 (9.6)
Means (SD) or percentages or medians (interquartile ranges) are shown.
Bold type and * indicates significant difference (P < 0.05) between intervention and placebo.
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women who had a more recent menopause compared to women who
did not.
Discussion
Among postmenopausal overweight and obese women, we found
that randomization to lifestyle change was associated with weight
loss compared to placebo and increases in FSH over a 1-year
period, although the magnitude of the FSH increase was small com-
pared to the baseline FSH value. Among women who did not use
estrogen, increases in FSH occurred in the lifestyle change arm
compared to placebo despite lack of statistically significant change
in E2 levels, although women in all randomization arms had
decreases in E2 levels. Changes in FSH were strongly correlated
with changes in E2, but FSH increases were correlated with weight
and waist circumference decreases even after adjustment for
changes in E2.
Our results support the hypothesis that weight loss increases FSH
levels among overweight and obese postmenopausal women. This is
consistent with previous observational studies that have reported that
body mass is associated with FSH levels. Using data from the Study
of Women’s Health Across the Nation (SWAN), Tepper et al
reported that FSH levels followed 3 patterns over the menopausal
transition: low, medium, and high FSH increases (2). Approximately
20% of obese women had FSH levels that fell into the low trajec-
tory, with average FSH levels of about 20 IU/l at 1 year after the
final menstrual period and of about 35 IU/l at 8 years after the final
menstrual period. Conversely, obese and overweight women were
less likely than lean women to fall into the high trajectory; lean
women were more likely to have FSH levels that exceeded 100 IU/l
at 1 year after the final menstrual period. Freeman et al have also
reported that FSH level is inversely associated with BMI category,
with heavier women having lower FSH levels in the postmenopause
(1). Wildman et al., (9) also using SWAN data, reported that current
waist circumference levels predicted future FSH. Among postmeno-
pausal women with FSH levels of 60 IU/l, each centimeter
increase in waist circumference was associated with approximately a
0.8 IU/l lower FSH.
We observed smaller increases in FSH subsequent to changes in
body size than observed in previous observational studies, perhaps
because women in the DPP were still overweight and centrally
obese even after significant weight loss. Our results demonstrate that
reductions in BMI as small as 2.5 kg/m2 in obese women (equiva-
lent to a loss of about 6.5 kg or 14 pounds) led to increases in FSH.
This suggests that the hypothalamic-pituitary-gonadal axis in over-
weight and obese women is still sensitive to weight changes among
women who have been postmenopausal for years, even though
women were, on average, still overweight or obese even after signif-
icant weight loss, and the FSH changes were fairly small. These
results in postmenopausal women contrast with a small study in pre-
menopausal obese women (mean weight, 120 kg) that reported no
FSH change even with 13 kg of weight loss (20). This suggests that
the FSH levels in obese premenopausal women might be insensitive
to weight fluctuations if obesity was still present after weight loss,
perhaps due to greater amounts of E2 produced by functioning
ovaries.
We also found that FSH increases tended to track more strongly
with E2 decreases rather than body mass changes. In the DPP,
weight loss was achieved through a combination of percent fat
reduction and physical activity in the lifestyle modification arm, and
due to the randomization scheme, the separate impact of these two
modifications apart from weight could not be examined by random-
ization arm; however, correlations between FSH or E2 with changes
in percent fat intake, alcohol intake, total caloric intake, and leisure-
time physical activity were not significant. Previous studies have
suggested that weight loss achieved through dietary changes (partic-
ularly reduction in fat) and exercise are linked to changes in E2,
although the effects of macronutrient intake and activity appear to
be minimal if significant weight loss does not occur (21-23). To our
TABLE 2 Changes in anthropometrics, FSH, and E2 between baseline and year 1 by randomization arm
Lifestyle Metformin Placebo
P value for
lifestyle vs.
placebo
P value for
metformin vs.
placebo
P value for
overall difference
between arms
Change in alcohol intake
per day (g)
20.11 (3.50) 0.64 (4.74) 20.16 (1.19) 0.81 0.54 0.13
Change in total kcal
consumption (kcal)
2434 (809) 2297 (691) 2310 (883) 0.13 0.91 0.35
Change in percent
calories from fat
25.8 (8.2) 21.5 (7.7) 20.7 (7.0) <0.0001 0.41 <0.0001
Change in leisure-time physical activity
(MET-hours/week)
5.0 (22.6) 20.3 (15.3) 4.4 (33.1) 0.0002 0.43 0.18
Change in weight (kg) 26.5 (6.0) 23.2 (5.3) 21.0 (3.6) <0.0001 0.0001 <0.0001
Change in waist
circumference (cm)
26.5 (6.1) 23.0 (5.3) 21.3 (5.3) <0.0001 0.01 <0.0001
Change in BMI (kg/m2) 22.5 (2.3) 21.2 (2.1) 20.4 (1.4) <0.0001 <0.0001 <0.0001
Change in FSH (IU/l) 2.3 (10.9) 1.3 (8.6) 20.81 (8.9) 0.0006 0.24 0.11
Change in E2 (pg/ml) 28.3 (7.6) 29.2 (7.0) 28.4 (9.6) 0.26 0.45 0.71
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knowledge, changes in FSH were not examined. Serum E2 levels
have been believed to be the primary pathway through which weight
influences FSH levels in postmenopausal women. In the absence of
ovarian E2 production, adipose tissue production of E2 from estro-
gen and androgen precursors has been believed to be the primary
source of serum E2. However, E2 made in most peripheral tissues
may be present in relatively small amounts in the circulation. While
FSH and E2 levels are not commonly measured in trials of estrogen
therapy, at least two randomized trials have reported that estrogen
supplementation can triple serum E2 levels (4,5), and FSH levels
are subsequently halved (5). The degree of FSH increase was not
reported to vary by weight (5), suggesting that exogenous E2 was
more influential than weight upon FSH levels in postmenopausal
women. The supraphysiologic levels of E2 in postmenopausal
women secondary to exogenous estrogen with resulting effects on
FSH may not reflect the FSH-E2 relationship at the lower levels of
E2 typically observed among women not using estrogen therapy.
However, previous observational studies have also reported that
higher levels of E2 in the postmenopause are associated with lower
FSH levels. Tepper et al. (2) reported that women with low FSH tra-
jectories were most likely to occur with higher E2 levels in the post-
menopause, with almost all women who fell into these trajectories
having BMIs  30 kg/m2.
While changes in E2 were most strongly correlated with changes in
FSH, changes in FSH were still associated with changes in weight
even after adjustment for E2. Moreover, changes in anthropometrics
and changes in E2 did not have strong correlations in our postmeno-
pausal overweight population. Observational studies of obese women
have suggested that correlations between E2 and anthropometrics
tend to be reduced among obese women, perhaps due to large
amounts of overall body fat (24). This suggests that adiposity-
related factors other than E2 may have affected FSH secretion.
Therefore, it may be that the prognostic value of FSH for either
menopausal staging or other clinical applications might be improved
with the measurement of additional markers. Although candidate
factors were not examined in this report and are speculative, such
factors include other estrogens such as estrone, as well as inhibin B,
adiponectin, leptin, and ghrelin, which have been previously
reported to be associated with FSH as well as weight (25-29).
Strengths of our report include its randomized design and interven-
tions which successfully induced statistically and clinically signifi-
cant amounts of weight loss. Our report also had several limitations.
Women were overweight or obese and glucose intolerant, and these
results may not apply to women who were metabolically healthy.
Although it is possible that a larger sample size would have
increased the statistical significance of some of the observed associ-
ations, such as between changes in weight and changes in E2 pro-
duction, the sample size was adequate to detect clinically significant
changes. Although we used mass spectrometry which is more reli-
able at lower levels of sex steroid measurement, variance at these
lower levels was high and possibly related to unreported estrogen
intake. Although change in weight was correlated with change in
FSH levels, we were unable to examine other estrogens such as
estrone, adipokines (leptin, ghrelin, adiponectin) or inhibin B levels
that might have mediated such associations. Because of sample size,
we were unable to examine the impact of menopause type upon sex
hormone levels in response to randomization. Finally, this study was
a secondary analysis of a randomized trial not designed a priori to
assess the impact of interventions on FSH concentrations.TA
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We conclude that weight reductions may lead to increases in FSH
levels in postmenopausal overweight and obese women, and such
changes may result from either reduction in E2 concentrations or
other adiposity-linked markers. These results suggest that the gonad-
otropin axis is sensitive to both serum sex steroids and body compo-
sition signaling mechanisms in overweight and obese women even
years after the final menstrual period. These results also replicate
that finding that even among overweight and obese women, endoge-
nous estrogen production does not suppress FSH production to the
extent that FSH levels replicate premenopausal levels. Further inves-
tigation of the impact of FSH changes among women with natural
and surgical menopause should be conducted. FSH is used as a
prognostic marker for success in assisted reproductive technologies
as well as supportive diagnostic evidence for conditions of menstrual
irregularities including polycystic ovarian syndrome and hypothala-
mic amenorrhea. While our report did not examine premenopausal
or perimenopausal women, our results suggest that weight and
weight loss might affect the value of FSH in these applications, and
further investigation should be conducted of the relationship
between weight loss and FSH in these populations.O
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